PMID- 18823531
OWN - NLM
STAT- MEDLINE
DCOM- 20081106
LR  - 20181113
IS  - 1475-2875 (Electronic)
IS  - 1475-2875 (Linking)
VI  - 7
DP  - 2008 Sep 29
TI  - Development of behaviour change communication strategy for a vaccination-linked 
      malaria control tool in southern Tanzania.
PG  - 191
LID - 10.1186/1475-2875-7-191 [doi]
AB  - BACKGROUND: Intermittent preventive treatment of malaria in infants (IPTi) using 
      sulphadoxine-pyrimethamine and linked to the expanded programme on immunization 
      (EPI) is a promising strategy for malaria control in young children. As evidence 
      grows on the efficacy of IPTi as public health strategy, information is needed so 
      that this novel control tool can be put into practice promptly, once a policy 
      recommendation is made to implement it. This paper describes the development of a 
      behaviour change communication strategy to support implementation of IPTi by the 
      routine health services in southern Tanzania, in the context of a five-year 
      research programme evaluating the community effectiveness of IPTi. METHODS: Mixed 
      methods including a rapid qualitative assessment and quantitative health facility 
      survey were used to investigate communities' and providers' knowledge and 
      practices relating to malaria, EPI, sulphadoxine-pyrimethamine and existing 
      health posters. Results were applied to develop an appropriate behaviour change 
      communication strategy for IPTi involving personal communication between mothers 
      and health staff, supported by a brand name and two posters. RESULTS: Malaria in 
      young children was considered to be a nuisance because it causes sleepless 
      nights. Vaccination services were well accepted and their use was considered the 
      mother's responsibility. Babies were generally taken for vaccination despite 
      complaints about fevers and swellings after the injections. 
      Sulphadoxine-pyrimethamine was widely used for malaria treatment and intermittent 
      preventive treatment of malaria in pregnancy, despite widespread rumours of 
      adverse reactions based on hearsay and newspaper reports. Almost all health 
      providers said that they or their spouse were ready to take SP in pregnancy (96%, 
      223/242). A brand name, key messages and images were developed and pre-tested as 
      behaviour change communication materials. The posters contained public health 
      messages, which explained the intervention itself, how and when children receive 
      it and safety issues. Implementation of IPTi started in January 2005 and 
      evaluation is ongoing. CONCLUSION: Behaviour Change Communication (BCC) 
      strategies for health interventions must be both culturally appropriate and 
      technically sound. A mixed methods approach can facilitate an interactive process 
      among relevant actors to develop a BCC strategy.
FAU - Mushi, Adiel K
AU  - Mushi AK
AD  - Ifakara Health Institute, P,O, Box 78373, Dar es Salaam, Tanzania. 
      adiel.mushi@lshtm.ac.uk
FAU - Schellenberg, Joanna
AU  - Schellenberg J
FAU - Mrisho, Mwifadhi
AU  - Mrisho M
FAU - Manzi, Fatuma
AU  - Manzi F
FAU - Mbuya, Conrad
AU  - Mbuya C
FAU - Mponda, Haji
AU  - Mponda H
FAU - Mshinda, Hassan
AU  - Mshinda H
FAU - Tanner, Marcel
AU  - Tanner M
FAU - Alonso, Pedro
AU  - Alonso P
FAU - Pool, Robert
AU  - Pool R
FAU - Schellenberg, David
AU  - Schellenberg D
LA  - eng
PT  - Journal Article
DEP - 20080929
PL  - England
TA  - Malar J
JT  - Malaria journal
JID - 101139802
RN  - 0 (Drug Combinations)
RN  - 37338-39-9 (fanasil, pyrimethamine drug combination)
RN  - 88463U4SM5 (Sulfadoxine)
RN  - Z3614QOX8W (Pyrimethamine)
SB  - IM
MH  - Chemoprevention/*methods
MH  - Communicable Disease Control/*methods
MH  - Drug Combinations
MH  - Education/methods
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Malaria/epidemiology/*prevention & control
MH  - Patients
MH  - Pregnant Women
MH  - Pyrimethamine/*therapeutic use
MH  - Sulfadoxine/*therapeutic use
MH  - Tanzania/epidemiology
MH  - *Vaccination
PMC - PMC2567329
EDAT- 2008/10/01 09:00
MHDA- 2008/11/07 09:00
PMCR- 2008/09/29
CRDT- 2008/10/01 09:00
PHST- 2008/05/07 00:00 [received]
PHST- 2008/09/29 00:00 [accepted]
PHST- 2008/10/01 09:00 [pubmed]
PHST- 2008/11/07 09:00 [medline]
PHST- 2008/10/01 09:00 [entrez]
PHST- 2008/09/29 00:00 [pmc-release]
AID - 1475-2875-7-191 [pii]
AID - 10.1186/1475-2875-7-191 [doi]
PST - epublish
SO  - Malar J. 2008 Sep 29;7:191. doi: 10.1186/1475-2875-7-191.